PPT - Blood Journal

Impact of ruxolitinib on the natural history of primary
myelofibrosis: a comparison of the DIPSS and the
COMFORT-2 cohorts
by Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro
Maria Vannucchi, Enrica Morra, Tiziano Barbui, Domenica Caramazza, Lisa Pieri,
Elisa Rumi, Heinz Gisslinger, Laurent Knoops, Jean Jaques Kiladjian, Barbara Mora,
Norbert Hollaender, Cristiana Pascutto, Claire Harrison, and Mario Cazzola
Blood
Volume 123(12):1833-1835
March 20, 2014
©2014 by American Society of Hematology
Survival estimate from diagnosis of PMF patients who become intermediate-2 and high risk IPSS
with a blast cell count <10% at any time of their follow-up according to the COMFORT-2 (n = 100)
and DIPSS (N = 350) cohorts.
Francesco Passamonti et al. Blood 2014;123:1833-1835
©2014 by American Society of Hematology